240 related articles for article (PubMed ID: 24469345)
1. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
Lazzaro C; Lopiano L; Cocito D
Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
[TBL] [Abstract][Full Text] [Related]
2. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
[TBL] [Abstract][Full Text] [Related]
5. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Goyal NA; Karam C; Sheikh KA; Dimachkie MM
Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
[TBL] [Abstract][Full Text] [Related]
10. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.
Markvardsen LH; Harbo T
J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
[TBL] [Abstract][Full Text] [Related]
15. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
16. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
20. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Blood Transfus; 2020 Mar; 18(2):96-105. PubMed ID: 32271703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
